<div id="readability-page-1"><p>Penumbra, Inc. (NYSE:PEN - Get Free Report) has been assigned a consensus rating of &#34;Hold&#34; from the seventeen analysts that are currently  covering the company, MarketBeat Ratings reports. Fourteen research analysts have rated the stock with a hold recommendation and three have issued  a buy recommendation on  the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $361.3333.</p><ul><li>3 Mid-Cap Medical Stocks Outperforming the Market</li></ul><p>Several equities analysts have weighed in on PEN shares. Wall Street Zen raised Penumbra to a &#34;hold&#34; rating in a research report on Saturday. Robert W. Baird  reissued a &#34;neutral&#34; rating and set a $374.00 price target (up from $345.00) on shares of Penumbra in a research report on Friday, January 16th. William Blair downgraded Penumbra from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Thursday, January 15th. Evercore  reaffirmed an &#34;outperform&#34; rating and issued a $335.00 price objective on shares of Penumbra in a research report on Thursday. Finally, Wells Fargo &amp; Company  reaffirmed an &#34;equal weight&#34; rating and issued a $374.00 price objective on shares of Penumbra in a research report on Thursday, January 15th.</p><p><b>View Our Latest Research Report on PEN</b></p><h2>Insiders Place Their Bets</h2><ul><li>Are These Medical Device Makers Getting Ready To Rally? </li></ul><p>In other news, CFO Maggie Yuen sold 2,432 shares of Penumbra stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $342.30, for a total value of $832,473.60. Following the completion of the sale, the chief financial officer owned 18,353 shares of the company's stock, valued at $6,282,231.90. The trade was a 11.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, Director Harpreet Grewal sold 100 shares of Penumbra stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director directly owned 8,719 shares of the company's stock, valued at approximately $2,861,750.18. This represents a 1.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by insiders. </p><h2>Institutional Investors Weigh In On Penumbra</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC grew its position in shares of  Penumbra by 2.3% in the fourth quarter. Hsbc Holdings PLC now owns 1,527 shares of the company's stock valued at $475,000 after purchasing an additional 35 shares during the period.  Farther Finance Advisors LLC boosted its holdings in  Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company's stock valued at $55,000 after acquiring an additional 38 shares during the last quarter.  Swiss Life Asset Management Ltd boosted its holdings in  Penumbra by 2.3% in the fourth quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company's stock valued at $537,000 after acquiring an additional 39 shares during the last quarter.  Abbot Financial Management Inc. boosted its holdings in  Penumbra by 1.3% in the third quarter. Abbot Financial Management Inc. now owns 3,254 shares of the company's stock valued at $824,000 after acquiring an additional 42 shares during the last quarter.  Finally, Glenview Trust Co boosted its holdings in  Penumbra by 5.0% in the third quarter. Glenview Trust Co now owns 904 shares of the company's stock valued at $229,000 after acquiring an additional 43 shares during the last quarter. Hedge funds and other institutional investors own  88.88% of the company's stock. </p><h2>Penumbra Stock Performance</h2><p>Penumbra stock opened at $321.64 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.95 and a current ratio of 6.02. The stock has a fifty day moving average of $332.48 and a two-hundred day moving average of $317.06. The company has a market capitalization of $12.65 billion, a price-to-earnings ratio of 74.11, a PEG ratio of 1.97 and a beta of 0.74. Penumbra has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. </p><p>Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.24). The company had revenue of $374.76 million for the quarter, compared to analysts' expectations of $370.47 million. Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The business's quarterly revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.83 EPS.  On average, analysts anticipate that  Penumbra will post 5.08 EPS for the current fiscal year. </p><h2>Penumbra Company Profile</h2> (Get Free Report)<p>Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.  </p><p>At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Penumbra</li><li>Before the Moon Base Gets Built, These 4 Companies Win</li><li>Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases</li><li>3 Stocks That Win If Inflation Surprises to the Downside</li><li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Penumbra Right Now?</h2><p>Before you consider Penumbra, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.</p><p>While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Penumbra, Inc. (NYSE:PEN) has received a consensus rating of "Hold" from 17 analysts, with 14 recommending hold and 3 suggesting buy. The average 1-year price target is $361.33. Recent analyst reports include a hold rating from Wall Street Zen and a neutral rating from Robert W. Baird with a price target increase to $374. CFO Maggie Yuen and Director Harpreet Grewal recently sold shares, reducing their ownership. Institutional investors hold 88.88% of the stock. Penumbra's stock opened at $321.64, with a market cap of $12.65 billion and a P/E ratio of 74.11.</p>

Market Beat

Penumbra

VanEck Biotech ETF

iShares US Medical Devices

SPDR S&P Health Equip

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Evercore

Wells Fargo

HSBC

HSBC HOLDINGS

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

HSBC 5xShortSG241213

HSBC Holdings Plc

Penumbra, Inc. (NYSE:PEN) Receives Consensus Rating of "Hold" from Analysts